排尿障害の新しい概念とその薬物治療　　２．過活動膀胱の病態と薬物治療

• 吉田 正貴

  熊本大学大学院医学薬学研究部泌尿器病態学 熊本労災病院泌尿器科

• 永田 卓士

  熊本大学大学院医学薬学研究部泌尿器病態学

• 桝永 浩一

  熊本大学大学院医学薬学研究部泌尿器病態学

• 宮本 豊

  熊本労災病院泌尿器科

• 工藤 惇三

  熊本労災病院泌尿器科

書誌事項

タイトル別名

• 2. Pathophysiology and Pharmacotherapy of Overactive Bladder

抄録

Overactive bladder (OAB) syndrome, which is characterized by a complex of storage symptoms (urinary urgency, frequency, nocturia and urgency incontinence) is highly prevalent in the general population; it causes significant distress to patients in terms of their psychosocial and physical functioning. Muscarinic receptors of bladder smooth muscles are involved in both normal and involuntary detrusor contraction (detrusor overactivity). Up-regulation of the muscarinic receptor function may contribute to the pathophysiology of OAB. In addition, several reports have suggested that various stimulations release many substances (ATP, prostaglandins, nitric oxide and acetylcholine) from bladder urothelium, which contribute to the pathophysiology of the increased bladder sensation, OAB symptoms and detrusor overactivity. The bladder urothelium also prossesses the non-neuronal cholinergic system and high density of muscarinic receptors. The roles and functions of the non-neuronal cholinergic system in OAB are currently under evaluation. Furthermore, new action sites of anticholinergic drugs have also been proposed. In this review, in addition to the pathophysiology of detrusor overactivity and OAB, the pharmacotherapy for OAB is discussed.

収録刊行物

• 臨床薬理

  臨床薬理 40 (5), 201-206, 2009

  一般社団法人 日本臨床薬理学会

キーワード

• overactive bladder
• muscarinic receptor
• anticholinergic drug
• urothelium

詳細情報

• CRID: 1390282680343397120
• NII論文ID: 130004541332
• DOI: 10.3999/jscpt.40.201
• ISSN: 18828272
• ISSN: 03881601
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可